Generative AI in Drug Discovery Market Report 2026

The generative artificial intelligence (AI) in drug discovery market size has grown exponentially in recent years. It will grow from $0.25 billion in 2025 to $0.33 billion in 2026 at a compound annual growth rate (CAGR) of 30.6%. The growth in the historic period can be attributed to high drug development costs, growth in computational chemistry, availability of biological datasets, adoption of machine learning tools, pharmaceutical r&d investment.

The generative artificial intelligence (AI) in drug discovery market size is expected to see exponential growth in the next few years. It will grow to $0.86 billion in 2030 at a compound annual growth rate (CAGR) of 27%. The growth in the forecast period can be attributed to integration of generative models in pipelines, demand for faster drug discovery, expansion of biologics optimization, collaboration between ai firms and pharma, reduced time-to-market. Major trends in the forecast period include rising adoption of AI-driven molecule generation, increased use of deep learning in drug design, expansion of small molecule discovery applications, growing integration of ai in lead optimization, accelerated early-stage drug development.

The increasing number of clinical trials is expected to drive the growth of the generative AI in drug discovery market. Clinical trials involve human participants and evaluate the safety and effectiveness of new medical treatments or procedures, generating scientific data on their suitability for human use. The growth in clinical trials is mainly driven by advancements in medical research, rising disease burden, regulatory changes, globalization of clinical research, patient awareness and advocacy, industry competition, technological innovation, and increased funding opportunities. Data from these trials feed generative AI models, accelerating drug discovery by predicting interactions and designing compounds. This integration supports personalized medicine, optimizes treatment effectiveness, enhances patient outcomes, and transforms the pharmaceutical landscape. For instance, in January 2025, Pharmaceutical Technology, a UK-based business news and media company, reported that 3,213 clinical trials are planned for the year, including 823 in Phase I and 1,102 in Phase II. Oncology is expected to remain the leading therapeutic area with 946 trials, followed by the central nervous system with 686 trials, and cardiovascular conditions with 258 trials. Therefore, the rising number of clinical trials is driving the generative AI in drug discovery market.

Key companies in the generative AI in drug discovery market are developing advanced AI-powered tools to accelerate drug development processes. These AI tools streamline drug discovery, design, and clinical trials using predictive analytics and machine learning. They improve efficiency in target identification, compound screening (including virtual screening using AI), preclinical development, regulatory compliance, and manufacturing. For example, in May 2023, Google Cloud, a US-based cloud computing service provider, launched two AI-driven solutions: the Target and Lead Identification Suite and the Multiomics Suite. The Target and Lead Identification Suite helps researchers understand amino acid functions and predict protein structures, while the Multiomics Suite accelerates the analysis of genomic data, supporting the development of personalized treatments for biotech, pharmaceutical, and public sector organizations.

In May 2023, Recursion Pharmaceuticals, a US-based clinical-stage TechBio company, acquired Cyclica and Valence for $40 million and $47.5 million, respectively. These acquisitions enhanced Recursion’s drug discovery capabilities through advanced AI technologies, positioning the company as a hub for top-tier AI and machine learning talent poised to drive innovation in drug discovery. Cyclica Inc., a Canada-based biotechnology company, specializes in data-driven drug discovery, biophysics, and AI to develop predictive analytics software, while Valence Labs, also based in Canada, focuses on advancing AI-driven research in drug discovery.

Major companies operating in the generative artificial intelligence (AI) in drug discovery market are Bayer AG, NVIDIA Corporation, Merck KGaA, IBM Research, Schrödinger Inc., Valo Health, BenevolentAI, XtalPi Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Exscientia, Atomwise Inc., InveniAI LLC, Healx, Aitia, Cloud Pharmaceuticals Inc., Optibrium, Aiforia, BioSymetrics Inc., Collaborations Pharmaceuticals Inc., MAbSilico, Reverie Labs, Standigm Inc., DeepMatter Group Limited, Variational AI Inc.

North America was the largest region in the generative AI in drug discovery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generative artificial intelligence (AI) in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the generative artificial intelligence (AI) in drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the generative artificial intelligence in drug discovery market by increasing costs of imported computing infrastructure, specialized hardware, and software platforms. Pharmaceutical and biotechnology companies are most affected due to reliance on high-performance imported systems. These tariffs raise research costs but support domestic ai technology development.

The generative artificial intelligence (AI) in drug discovery market research report is one of a series of new reports that provides generative artificial intelligence (AI) in drug discovery market statistics, including generative artificial intelligence (AI) in drug discovery industry global market size, regional shares, competitors with a generative artificial intelligence (AI) in drug discovery market share, detailed generative artificial intelligence (AI) in drug discovery market segments, market trends and opportunities, and any further data you may need to thrive in the generative artificial intelligence (AI) in drug discovery industry. This generative artificial intelligence (AI) in drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Generative AI in drug discovery refers to the use of advanced machine learning, particularly generative models, to design and identify new pharmaceutical compounds. These AI systems analyze large datasets, including chemical properties, biological activities, and existing drug information, to predict and generate novel molecules with potential therapeutic benefits. The main goal of generative AI in drug discovery is to accelerate the identification and development of new pharmaceutical compounds with therapeutic potential, streamlining the drug development process by efficiently leveraging extensive data to generate new molecules.

The main types of generative AI in drug discovery are small molecules and large molecules. Small molecules are chemically synthesized drugs that typically have low molecular weight. The technologies used include deep learning, machine learning, reinforcement learning, molecular docking, and quantum computing. These are utilized by various end-users, including pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations (CROs), and others.

The generative AI in drug discovery market includes revenues earned by entities by providing services such as molecule generation, optimization, virtual screening, predictive modeling, de novo drug design, and consulting support. The market value includes the value of related goods sold by the service provider or included within the service offering. The generative AI in drug discovery market also includes sales of quantum computers, high-performance computing (HPC) clusters, tensor processing units, graphics processing units, and preclinical development tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.